Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.7363
-0.0297 (-3.88%)
At close: Aug 10, 2026, 4:00 PM EDT
0.7234
-0.0129 (-1.75%)
After-hours: Aug 10, 2026, 6:40 PM EDT
Longeveron Employees
Longeveron had 38 employees as of December 31, 2025. The number of employees increased by 12 or 46.15% compared to the previous year.
Employees
38
Change (1Y)
12
Growth (1Y)
46.15%
Revenue / Employee
$32,000
Profits / Employee
-$590,237
Market Cap
24.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 38 | 12 | 46.15% | 38 | 0 |
| Dec 31, 2024 | 26 | 2 | 8.33% | 26 | 0 |
| Dec 31, 2023 | 24 | 3 | 14.29% | 23 | 1 |
| Dec 31, 2022 | 21 | 1 | 5.00% | 19 | 2 |
| Dec 31, 2021 | 20 | 8 | 66.67% | 18 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Evaxion | 46 |
| NextCure | 40 |
| Actinium Pharmaceuticals | 25 |
| ABVC BioPharma | 19 |
| Tevogen | 18 |
| Quantum BioPharma | 17 |
| Barinthus Biotherapeutics | 14 |
LGVN News
- 7 days ago - Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 - GlobeNewsWire
- 18 days ago - Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors - GlobeNewsWire
- 4 weeks ago - Longeveron presents positive laromestrocel data in Alzheimer’s disease - TheFly
- 4 weeks ago - Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Longeveron appoints Marie Washburn CFO - TheFly
- 5 weeks ago - Longeveron® Appoints Marie Washburn as Chief Financial Officer - GlobeNewsWire
- 5 weeks ago - Longeveron Transcript: AGM 2026 - Transcripts
- 7 weeks ago - New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) - GlobeNewsWire